10 results about "Emodin" patented technology

The application discloses a kind of magnetic therapy traditional Chinese medicine sustained-release suppository and its preparation method and purposes, belong to medical technical field.The suppository includes medicine layer and magnetic therapy component;Medicine layer is composed of mixed matrix and sustained-release regulator, wherein mixed matrix includes traditional Chinese medicine extraction mixture and sustained-release matrix, and the active ingredient of traditional Chinese medicine extraction mixture is compounded by emodin, aloe glycoside and angelica volatile oil according to mass ratio 3:2:1, and sustained-release matrix is formed by mixing PEG4000 and PEG6000 according to mass ratio 3:2;Sustained-release regulator is HPMCK15M, and the addition amount is 0.5% of the total mass of mixed matrix;Magnetic therapy component is neodymium iron boron permanent magnet arranged in the tail of suppository.The application realizes three-stage ladder release, matches human physiological defecation rhythm, and simultaneously magnetic field enhances colon target absorption;It is suitable for treating slow transit constipation or outlet obstruction constipation, and has the advantages of mild laxative, spasmolysis repair, low stimulation and low dependence.

This invention belongs to the field of pesticide technology, specifically relating to a pesticide composition containing benzimidazole. The pesticide composition's active ingredient is a compound of benzimidazole and fluazinam or emodin methyl ether. This invention, through indoor bioactivity tests, found that the compound of benzimidazole with fluazinam or emodin methyl ether, within a certain mass ratio range, has a synergistic effect against various plant fungal diseases such as Rhizoctonia solani, Curvularia crescentis, and Sclerotium sclerotiorum, helping to improve control efficacy. This is of great significance for the research and development of pesticides for controlling diseases such as cucumber damping-off, corn curvularia leaf spot, and peanut white mold.

This invention discloses an emodin-modified amine curing agent and its preparation method, as well as a long-lasting anti-corrosion coating based on bulk rust conversion, its preparation method, and its application. It relates to the field of anti-corrosion coating technology. The preparation method of the emodin-modified amine curing agent of this invention includes: subjecting raw materials including 2-hydroxyemodin, formaldehyde, and 1,5-pentanediamine to a Mannich reaction to obtain the emodin-modified amine curing agent. The emodin-modified amine curing agent used in this invention has a certain rust conversion ability and forms a stable chelate with iron ions, eliminating the need for rust conversion agents and allowing direct application to corroded surfaces. By using a suitable resin and curing agent system ratio, this invention can prepare a high-performance, low-surface-treatment, long-lasting anti-corrosion coating based on bulk rust conversion, applicable to manually cleaned surfaces (St2 / St3, ISO 8501-1), old coatings, high-pressure water jetting, and wet sandblasting substrate surfaces.

This application relates to the field of genetically engineered bacteria technology, specifically disclosing a genetically engineered *E. coli* strain for producing emodin, its construction method, and its applications. This application uses *E. coli* BAP1 as the substrate strain. This strain carries its own sfp in its genome, which can be used to activate polyketide synthase. Furthermore, *E. coli* itself grows rapidly, has a vigorous metabolism, and the culture medium is low-cost, facilitating high-density fermentation. Through gene editing, the uptake and utilization of glucose are improved, the flux of acetic acid and lactic acid diverted from pyruvate is reduced, and the ATP supply is enhanced to increase the flux of acetyl-CoA and malonyl-CoA within the bacteria. This provides sufficient substrate for the synthesis of emodin by polyketide synthase, thioesterase, and decarboxylase, thereby increasing the yield of emodin. The emodin yield achieved by this application through shake-flask fermentation reaches 576.4 mg / L, which is currently the highest level in the *E. coli* system.

This invention discloses a method for preparing TCPP / Emodin composite photocatalysts and their antibacterial applications, belonging to the field of pharmaceutical antibacterial medicine. Addressing the issues of drug resistance easily induced by traditional antibiotics in treating bacterial infections, performance defects in existing photocatalysts, and insufficient antibacterial capacity of single antibacterial materials, this invention leverages the advantages of tetracarboxyphenylporphyrin (TCPP)—strong visible light capture ability and low photogenerated electron-hole recombination rate—and complements emodin's π-conjugated system and its structural advantage of promoting carrier migration. The two are covalently linked through a chemical coupling mechanism involving EDC / NHS synergistic activation of the carboxyl group. Through steps such as dissolution, mixing reaction, dialysis purification, and freeze-drying, spherical TCPP / Emodin composite nanomaterials with a particle size of 100-500 nm are obtained. This composite material reduces the photogenerated electron-hole recombination rate and improves carrier migration efficiency, efficiently generating ROS under visible light irradiation, and exhibits excellent photodynamic antibacterial properties.

The present application belongs to the technical field of pesticides, and particularly relates to a biological pesticide for preventing and treating citrus red mite. The biological pesticide is prepared by compounding emodin with abamectin or osthole. When emodin is combined with abamectin or osthole, a synergistic effect is exhibited on the citrus red mite, the prevention and treatment effect on the citrus red mite can be improved, the problems caused by long-term use of the same type of pesticide or the same pesticide can be alleviated, the generation and development of the drug resistance of the citrus red mite can be delayed, and support is provided for the comprehensive management of the drug resistance. In addition, emodin, abamectin and osthole are all biological pesticide components, are environment-friendly and green, and can provide support for developing the biological pesticide for preventing and treating the citrus red mite.

The application relates to the technical field of kidney treatment, and particularly discloses a method for extracting emodin and application of the emodin in renal ischemia-reperfusion injury. The method comprises the following steps: S1, crushing traditional Chinese medicine rhubarb raw materials to obtain traditional Chinese medicine rhubarb powder; S2, mixing the traditional Chinese medicine rhubarb powder with ethanol and performing ultrasonic treatment to obtain a primary extraction solution; S3, adding cellulase to the primary extraction solution to obtain an enzymatic solution; S4, performing supercritical CO2 extraction on the enzymatic solution, and collecting an extraction phase; S5, adding ethyl acetate to the extraction phase for extraction, and then separating an organic phase; S6, crystallizing the organic phase, and filtering to obtain emodin crude products; and S7, recrystallizing the emodin crude products with methanol, and drying to obtain finished products. The method for extracting emodin can be used for preparing medicines for treating kidney diseases, in particular, renal ischemia-reperfusion injury, and has the advantages of high extraction efficiency, high product purity and a green and environment-friendly process.

This invention belongs to the field of agricultural biological control technology, specifically relating to *Trichoderma harzianum* IVF1 for controlling fungal diseases and its application. The *Trichoderma harzianum* (… Trichoderma harzianum The preservation number of this invention is CGMCC No. 42324. The *Trichoderma harzianum* strain of this invention can effectively inhibit gray mold in cucumbers and wilt disease in cowpeas. Under inactivated gray mold induction conditions, the antibacterial active substances produced by *Trichoderma harzianum* of this invention are increased, further enhancing the control efficacy. Transcriptome results show that differentially expressed genes are significantly enriched in pathways related to secondary metabolite biosynthesis, antibiotic synthesis, and amino acid synthesis. Metabolome results show that the production of important biologically active organic acids such as citric acid, benzene ring compound emodin, organic heterocyclic compound 6-methylnicotinic acid, and *Trichoderma diol* is significantly increased.

This invention provides a triptolide sustained-release hydrogel targeting the FOSB and TGFB1 axes and its applications, belonging to the field of biomedical materials and drug delivery technology. The sustained-release hydrogel is a core-shell structured sequential release hydrogel. The outer layer is a 40 mg / mL low-concentration gelatin methacrylamide hydrogel loaded with stromal cell-derived factor-1α (SDF-1α), and the inner layer is a 60 mg / mL high-concentration GelMA hydrogel loaded with triptolide. This invention is the first to clearly demonstrate that the transcription factor FOSB constitutes a core driving pathway for endometriosis fibrosis by transcribing and activating TGFB1. Triptolide can directly bind to FOSB and promote its ubiquitination-mediated degradation, thereby blocking the TGF-β / Smad signaling pathway and mesenchymal-myofibroblast transformation. Through a synergistic recruitment-targeted inhibition strategy using core-shell hydrogels, SDF-1α rapidly recruits myofibroblasts in the lesion area, and tripterygium wilfordii achieves local sustained release over 14 days. While significantly inhibiting fibrosis and reducing the size of endometriosis lesions, it avoids the hepatotoxicity and off-target damage of free drugs.

The application belongs to the technical field of biology, and discloses application of emodin-8-glucoside in preparation of a product for preventing and / or treating tangu virus infection; through in-vitro experiments using a recombinant duck tangu virus stably expressing EGFP, it is proved that emodin-8-glucoside can efficiently inhibit virus replication, and the half effective concentration (EC 50 ) thereof is as low as 1.935 μM, the half cytotoxicity concentration (CC 50 ) thereof is as high as 511.3 μM, the calculated therapeutic index (SI) is 264.24, and the compound has the outstanding characteristics of high efficiency and low toxicity, and is high in clinical application safety; through duck infection model experiments, it is proved that after treatment of emodin-8-glucoside, the virus load in the spleen of the infected duck can be extremely significantly reduced, and the reduction amplitude is as high as 99%, which indicates that emodin-8-glucoside can effectively inhibit the replication of DTMUV in the duck body, and has a definite therapeutic effect; meanwhile, the application also provides a medicine containing emodin-8-glucoside.